β-Cell failure in type 2 diabetes

Journal of Diabetes Investigation

Volumn 2, Issue 2, 2011, Pages 82-91

  Leibowitz, Gil ^a   Kaiser, Nurit ^a   Cerasi, Erol ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cell failure; Insulin resistance; Insulin secretion

Indexed keywords

GLUCOSE; GLUTAREDOXIN; INSULIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 2;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL COUNT; CELL FUNCTION; ENDOPLASMIC RETICULUM; GENE IDENTIFICATION; GENETIC RISK; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 79961044817     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00094.x     Document Type: Review

References (84)

1. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 304: 1279-1283.
2. Himsworth HP. High carbohydrate diets and insulin efficiency. Br Med J 1934; 2: 57-60.
3. Himsworth HP. Diabetes mellitus. Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 227: 127-130.
4. Saltiel AR. The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardio-vascular disease. J Clin Invest 2000; 106: 163-164.
5. Cerasi E, Luft R. Plasma insulin response to sustained hyper-glycaemia induced by glucose infusion in human subjects. Lancet 1963; 282: 1359-1361.
6. Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. Acta Endocrinol 1967; 55: 278-304.
7. Pyke DA, Taylor KW. Glucose tolerance and serum insulin in unaffected identical twins of diabetics. Br Med J 1967; 4: 21-22.
8. Seltzer HS, Allen EW, Herron AL, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967; 46: 323-335.
9. Soeldner JS, Gleason RE, Williams RF, et al. Diminished serum insulin response to glucose in genetic prediabetic males with normal glucose tolerance. Diabetes 1968; 17: 17-26.
10. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of type 2 diabetes: is a divorce possible? Diabetologia 1995; 38: 992-997.
11. Kulkarni RN, Bruning JC, Winnay JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-339.
12. Cavaghan MK, Ehrman DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-333.
13. Della Casa L, Del Rio G, Glaser B, et al. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous sub- cutaneous insulin infusion-induced normoglycemia. Am J Med 1991; 90: 37S-45S.
14. Ilkova H, Glaser B, Tunçkale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
15. Retnakaran R, Yakubovitch N, Qi Y, et al. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010; 12: 65-71.
16. Weng J, Li Y, Wen X, et al. Effect of intensive insulin therapy on ß-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
17. Efendic S, Cerasi E, Elander I, et al. Studies on low insulin responders. Acta Endocrinol 1979; 90(Suppl. 224): 5-32.
18. Hollenbeck CB, Chen N, Chen Y-DI, et al. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984; 33: 460-463.
19. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin- dependent diabetes mellitus. Prospective studies of Pima Indians. NEnglJMed1993; 329: 1988-1992.
20. Ferrannini E, Natali A, Bell P, et al. Insulin resistance and hypersecretion in obesity. J Clin Invest 1997; 100: 1166-1173.
21. Cerasi E, Efendic S, Luft R. Dose-response relationship of plasma insulin and blood glucose levels during oral glucose loads in prediabetic and diabetic subjects. Lancet 1973; 301: 794-797.
22. Hales CN. The pathogenesis of NIDDM. Diabetologia 1994; 37(Suppl. 2): S162-S168.
23. Ferrannini E, Gastaldelli A, Miyazaki Y, et al. β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
24. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
25. Pørksen N, Holligdal M, Juhl C, et al. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 2002; 51(Suppl. 1): S245-S254.
26. Seino Y, Fukushima N, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 8-23.
27. Alvarsson M, Wajngot A, Cerasi E, et al. K-value and low insulin secretion in a non-obese white population predicted glucose tolerance after 25 years. Diabetologia 2005; 48: 2262-2268.
28. Utzschneider KM, Prigeon RL, Faulenbach MV, et al. Oral dis- position index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009; 32: 335-341.
29. Cali AMG, Dalla Man C, Cobelli C, et al. Primary defects inβ-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care 2009; 32: 456-461.
30. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol 1967; 55: 330-345.
31. Pyke DA, Cassar J, Todd J, et al. Glucose tolerance and serum insulin in identical twins of diabetics. Br Med J 1970; 4: 649-651.
32. Iselius L, Lindsten J, Morton NE, et al. Genetic regulation of the kinetics of glucose-induced insulin release in man - studies in families with diabetic and non-diabetic probands. Clin Genet 1985; 28: 8-15.
33. Simonis-Bik AMC, Eekhoff EMW, de Moor MHM, et al. Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia 2009; 52: 2570-2577.
34. Staiger H, Machicao F, Fritsche A, et al. Pathomechanisms of type 2 diabetes genes. Endocr Rev 2009; 30: 557-585.
35. Pascoe L, Frayling TM, Weedon MN, et al. Beta cell glucose sensitivity is decreased by 39% in non-diabetic subjects car-rying multiple diabetes-risk alleles compared with those with no risk alleles. Diabetologia 2008; 51: 1989-1992.
36. t'Hart LM, Simonis-Bik AM, Nijpels G, et al. Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion dur- ing hyperglycaemic clamps. Diabetes 2010; 59: 287-292.
37. Gloyn AL, Braun M, Rorsman P. Type 2 diabetes susceptibility gene TCF7L2 and its role in β-cell function. Diabetes 2009; 58: 800-802.
38. Da Silva Xavier G, Loder MK, MacDonald A, et al. TCF7L2 reg- ulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 2009; 58: 894-905.
39. Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-2399.
40. Mondal AK, Das SK, Baldini G, et al. Genotype and tissue-specific effects on alternative splicing of the transcription factor 7-like 2 gene in humans. J Clin Endocrinol Metab 2010; 95: 1450-1457.
41. Vaxillaire M, Bonnefond A, Froguel P. Breakthroughs in monogenic diabetes genetics: from pediatric forms to young adulthood diabetes. Pediatr Endocrinol Rev 2009; 6: 405-417.
42. Hattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009; 10(Suppl. 12): 33-42.
43. Støy J, Steiner DF, Park SY et al. Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord 2010; 11: 205-215.
44. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006; 55(Suppl. 1): S2-S5.
45. Maclean N, Ogilvie RF. Quantitative estimation of the pancre- atic islet tissue in diabetic subjects. Diabetes 1955; 4: 367-376.
46. Gepts W. Die histopathologischen Veränderungen der Langerhansschen Inseln und ihre Bedeutung in der Frage des Pathogenese des menschlichen Diabetes. Endokrinologie 1958; 36: 185-211.
47. Saito K, Takahashi T, Yaginuma N, et al. Islet morphometry in the diabetic pancreas of man. Tohoku J Exp Med 1978; 125: 185-197.
48. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
49. Clark A, Jones LC, de Koning E, et al. Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function? Diabetes 2001; 50(Suppl. 1): S169-S171.
50. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta- cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002; 45: 85-96.
51. Yoon KH, Ko SH, Cho JH, et al. Selective b-cell loss and a-cell expansion in patients with type 2 diabetes mellitus in Korea. JClinEndocrMetab2003; 88: 2300-2308.
52. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10(Suppl. 4): 32-42.
53. Butler AE, Cao-Minh L, Galasso R, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 2010; 53: 2167-2176.
54. Ichise M, Harris PE. Imaging of beta-cell mass and function. JNuclMed2010; 51: 1001-1004.
55. Kaiser N, Yuli M, Üçkaya G, et al. Dynamic changes in beta-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus. Impact of glycemic control. Diabetes 2005; 54: 138-145.
56. Gunton JE, Kulkarni RN, Yim S, et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 2005; 122: 337-349.
57. Marselli L, Thorne J, Dahiya S, et al. Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS ONE 2010; 5: e11499.
58. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812.
59. Kaiser N, Leibowitz G. Failure of beta-cell adaptation in type 2 diabetes: lessons from animal models. Front Biosci 2009; 14: 1099-1115.
60. Cnop M, Hughes SJ, Igoillo-Esteve M, et al. The long lifespan and low turnover of human islet beta cells estimated by mathematical modelling of lipofuscin accumulation. Diabetologia 2010; 53: 321-330.
61. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
62. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. NEnglJMed 2007; 356: 1517-1526.
63. Song B, Scheuner D, Ron D, et al. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 2008; 118: 3378-3389.
64. Bachar E, Ariav Y, Ketzinel-Gilad M, et al. Glucose amplifies fatty acid-induced endoplasmic reticulum stress in pancreatic beta-cells via activation of mTORC1. PLoS ONE 2009; 4: e4954.
65. Huang CJ, Lin CY, Haataja L, et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticu- lum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007; 56: 2016-2027.
66. Kennedy J, Katsuta H, Jung MH, et al. Protective unfolded protein response in human pancreatic beta cells trans- planted into mice. PLoS ONE 2010; 5: e11211.
67. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 1996; 20: 463-466.
68. Tiedge M, Lortz S, Drinkgern J, et al. Relation between anti- oxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742.
69. Lacraz G, Figeac F, Movassat J, et al. Diabetic beta-cells can achieve self-protection against oxidative stress through an adaptive up-regulation of their antioxidant defenses. PLoS ONE 2009; 4: e6500.
70. Martens GA, Cai Y, Hinke S, et al. Glucose suppresses super-oxide generation in metabolically responsive pancreatic beta cells. J Biol Chem 2005; 280: 20389-20396.
71. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid Redox Signal 2000; 2: 811-820.
72. Ivarsson R, Quintens R, Dejonghe S, et al. Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin. Diabetes 2005; 54: 2132-2142.
73. Yoshioka J, Schreiter ER, Lee RT. Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 2006; 8: 2143-2151.
74. Patwari P, Higgins LJ, Chutkow WA, et al. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 2006; 281: 21884-21891.
75. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. JBiol Chem 2010; 285: 3997-4005.
76. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 2005; 146: 2397-2495.
77. Schulze PC, Yoshioka J, Takahashi T, et al. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. JBiolChem 2004; 279: 30369-30374.
78. Qi W, Chen X, Gilbert RE, et al. High glucose-induced thiore-doxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol 2007; 171: 744-754.
79. Turturro F, Friday E, Welbourne T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin- interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007; 7: 96.
80. Chen J, Saxena G, Mungrue IN, et al. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008; 57: 938-944.
81. Chen J, Hui ST, Couto FM, et al. Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 2008; 22: 3581-3594.
82. Shaked M, Ketzinel-Gilad M, Ariav Y, et al. Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 2009; 52: 636-644.
83. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-140.
84. Cerasi E, Luft R. "What is inherited - what is added "hypothesis for the pathogenesis of diabetes mellitus. Diabetes 1967; 16: 615-627.